We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Vertex Pharmaceuticals’ cystic fibrosis drug Trikafta (elexacaftor/tezacaftor/ivacaftor) will need a dramatic price cut to be cost effective, the Institute for Clinical and Economic Review (ICER) found in a new analysis. Read More
Sanofi and Regeneron have modified their clinical trial of the rheumatoid arthritis drug Kevzara (sarilumab) as a COVID-19 treatment after preliminary results found no benefit in one group. Read More
Pharmacy benefit manager (PBM) reimbursements to pharmacies have failed to keep up with price increases for generic drugs, according to an analysis by 3 Axis Advisors, a consulting group that tracks drug supply-chain inefficiencies and pricing. Read More
In a letter to the FDA last week, 35 federal lawmakers recommend the agency consider approving human “challenge” trials for COVID-19, which would infect healthy volunteers with the deadly virus to test efficacy of a vaccine. But the FDA and some researchers have expressed concern over the ethics involved. Read More
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is relaxing some GMP requirements to help manufacturers overcome challenges during the COVID-19 pandemic. Read More